ARK Genomic Revolution ETF
ARKG
59 hedge funds and large institutions have $65.5M invested in ARK Genomic Revolution ETF in 2018 Q3 according to their latest regulatory filings, with 19 funds opening new positions, 21 increasing their positions, 5 reducing their positions, and 6 closing their positions.
320% more repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 5
217% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 6
95% more capital invested
Capital invested by funds: $33.5M → $65.5M (+$31.9M)
28% more funds holding
Funds holding: 46 → 59 (+13)
2.9% more ownership
Funds ownership: 16.47% → 19.37% (+2.9%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$4.51M |
| 2 |
LPL Financial
San Diego,
California
|
+$3.45M |
| 3 |
SI
Stephens Inc
Little Rock,
Arkansas
|
+$3.28M |
| 4 |
PC
Passport Capital
San Francisco,
California
|
+$3.17M |
| 5 |
PCM
Penserra Capital Management
Orinda,
California
|
+$2.23M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jane Street
New York
|
-$2.71M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$1M |
| 3 |
EFS
Edelman Financial Services
Fairfax,
Virginia
|
-$163K |
| 4 |
LTFS
Ladenburg Thalmann Financial Services
Miami,
Florida
|
-$37.8K |
| 5 |
CFA
Carroll Financial Associates
Charlotte,
North Carolina
|
-$36.9K |
ARKG Hedge Fund Activity: Q3 2018 in Review
59 of the 4,391 institutional investors tracked by Wall St. Rank reported a position in ARK Genomic Revolution ETF (ARKG) for Q3 2018, worth a combined $65.5M — up 95% from $33.5M a quarter earlier.
Buyers outnumbered sellers: 19 funds opened new ARKG positions and 6 closed out — a net gain of 13 holders — while 21 added to existing stakes and 5 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $4.51M. The largest seller was Jane Street, exiting entirely with an estimated $2.71M sold.
- 59 institutional investors held ARK Genomic Revolution ETF (ARKG) as of Q3 2018, up from 46 in Q2 2018.
- Funds reported $65.5M of ARK Genomic Revolution ETF stock for Q3 2018, up 95% quarter-over-quarter.
- 19 funds opened new ARK Genomic Revolution ETF positions in Q3 2018 and 6 closed out, a net change of +13 holders.
- The largest ARK Genomic Revolution ETF buyer in Q3 2018 was Morgan Stanley, an estimated $4.51M added.
- The largest ARK Genomic Revolution ETF seller in Q3 2018 was Jane Street, an estimated $2.71M sold.
Based on aggregated 13F filings for Q3 2018.